alendronate has been researched along with Diabetes Mellitus, Type 2 in 18 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In premenopausal women with MDD, reduced daily adiponectin production may increase the risk of diabetes mellitus, and elevated leptin may contribute to osteoporosis." | 7.76 | Low 24-hour adiponectin and high nocturnal leptin concentrations in a case-control study of community-dwelling premenopausal women with major depressive disorder: the Premenopausal, Osteopenia/Osteoporosis, Women, Alendronate, Depression (POWER) study. ( Ahima, RS; Blackman, MR; Cizza, G; Duan, Z; Eskandari, F; Nguyen, VT; Reynolds, JC; Wright, EC, 2010) |
| "Alendronate (ALN) increases alveolar bone density with systemic use and, has been found to increase bone formation on local delivery into the periodontal pocket." | 5.16 | Local drug delivery of alendronate gel for the treatment of patients with chronic periodontitis with diabetes mellitus: a double-masked controlled clinical trial. ( Bajaj, P; Kumari, M; Naik, SB; Pradeep, AR; Rao, NS; Sharma, A, 2012) |
| " The pivotal phase 3 trial ACTIVE and its extension (ACTIVExtend) demonstrated the efficacy of initial treatment with ABL for 18 months followed by sequential treatment with alendronate (ALN) for an additional 24 months to reduce the risk of vertebral, nonvertebral, clinical, and major osteoporotic fractures and to increase BMD in postmenopausal women with osteoporosis." | 5.05 | Abaloparatide: an anabolic treatment to reduce fracture risk in postmenopausal women with osteoporosis. ( Bilezikian, JP; Bone, HG; Cosman, F; Fitzpatrick, LA; McCloskey, EV; Miller, PD; Mitlak, B, 2020) |
| " Bisphosphonates are first-line treatment of osteoporosis, and we aimed to investigate whether the risk of developing type 2 diabetes was associated with prior use of alendronate." | 4.02 | Alendronate Use and Risk of Type 2 Diabetes: A Nationwide Danish Nested Case-Control Study. ( Al-Mashhadi, Z; Starup-Linde, J; Vestergaard, P; Viggers, R, 2021) |
| " We aimed to investigate whether the risk of major osteoporotic fractures in diabetes patients differs between subjects initiated with alendronate and denosumab, respectively." | 4.02 | The Efficacy of Alendronate Versus Denosumab on Major Osteoporotic Fracture Risk in Elderly Patients With Diabetes Mellitus: A Danish Retrospective Cohort Study. ( Al-Mashhadi, Z; Starup-Linde, J; Vestergaard, P; Viggers, R, 2021) |
| "In premenopausal women with MDD, reduced daily adiponectin production may increase the risk of diabetes mellitus, and elevated leptin may contribute to osteoporosis." | 3.76 | Low 24-hour adiponectin and high nocturnal leptin concentrations in a case-control study of community-dwelling premenopausal women with major depressive disorder: the Premenopausal, Osteopenia/Osteoporosis, Women, Alendronate, Depression (POWER) study. ( Ahima, RS; Blackman, MR; Cizza, G; Duan, Z; Eskandari, F; Nguyen, VT; Reynolds, JC; Wright, EC, 2010) |
| "Alendronate (ALN) is an aminobisphosphonate commonly used for osteoporosis in postmenopausal women." | 2.70 | Clinical and radiological improvement of periodontal disease in patients with type 2 diabetes mellitus treated with alendronate: a randomized, placebo-controlled trial. ( Garay-Sevilla, ME; Malacara, JM; Nava, LE; Rocha, M; Sánchez-Márin, F; Vázquez de la Torre, C, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (44.44) | 29.6817 |
| 2010's | 5 (27.78) | 24.3611 |
| 2020's | 5 (27.78) | 2.80 |
| Authors | Studies |
|---|---|
| Viggers, R | 2 |
| Al-Mashhadi, Z | 2 |
| Starup-Linde, J | 2 |
| Vestergaard, P | 3 |
| Muche, B | 1 |
| Miller, PD | 1 |
| Bilezikian, JP | 1 |
| Fitzpatrick, LA | 1 |
| Mitlak, B | 1 |
| McCloskey, EV | 1 |
| Cosman, F | 1 |
| Bone, HG | 1 |
| Martini, C | 1 |
| Sosa, FN | 1 |
| Malvicini, R | 1 |
| Pacienza, N | 1 |
| Yannarelli, G | 1 |
| Del C Vila, M | 1 |
| Chan, DC | 1 |
| Yang, RS | 1 |
| Ho, CH | 1 |
| Tsai, YS | 1 |
| Wang, JJ | 1 |
| Tsai, KT | 1 |
| Lazarovici, TS | 1 |
| Yahalom, R | 1 |
| Taicher, S | 1 |
| Elad, S | 1 |
| Hardan, I | 1 |
| Yarom, N | 1 |
| Bocanegra-Pérez, S | 1 |
| Vicente-Barrero, M | 1 |
| Sosa-Henríquez, M | 1 |
| Gebaguer Blanco, A | 1 |
| Knezevic, M | 1 |
| Castellano-Navarro, JM | 1 |
| Cizza, G | 1 |
| Nguyen, VT | 1 |
| Eskandari, F | 1 |
| Duan, Z | 1 |
| Wright, EC | 1 |
| Reynolds, JC | 1 |
| Ahima, RS | 1 |
| Blackman, MR | 1 |
| Iwamoto, J | 1 |
| Sato, Y | 1 |
| Uzawa, M | 1 |
| Takeda, T | 1 |
| Matsumoto, H | 1 |
| Pradeep, AR | 1 |
| Sharma, A | 1 |
| Rao, NS | 1 |
| Bajaj, P | 1 |
| Naik, SB | 1 |
| Kumari, M | 1 |
| Maffei, L | 1 |
| Murata, Y | 1 |
| Rochira, V | 1 |
| Tubert, G | 1 |
| Aranda, C | 1 |
| Vazquez, M | 1 |
| Clyne, CD | 1 |
| Davis, S | 1 |
| Simpson, ER | 1 |
| Carani, C | 1 |
| Keegan, TH | 1 |
| Schwartz, AV | 1 |
| Bauer, DC | 1 |
| Sellmeyer, DE | 1 |
| Kelsey, JL | 1 |
| Ikeda, T | 1 |
| Manabe, H | 1 |
| Iwata, K | 1 |
| Yee, J | 1 |
| Cauley, JA | 1 |
| Ensrud, KE | 1 |
| Rocha, M | 1 |
| Nava, LE | 1 |
| Vázquez de la Torre, C | 1 |
| Sánchez-Márin, F | 1 |
| Garay-Sevilla, ME | 1 |
| Malacara, JM | 1 |
1 review available for alendronate and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Abaloparatide: an anabolic treatment to reduce fracture risk in postmenopausal women with osteoporosis.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Clinical Trials as Topic; Diab | 2020 |
4 trials available for alendronate and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Local drug delivery of alendronate gel for the treatment of patients with chronic periodontitis with diabetes mellitus: a double-masked controlled clinical trial.
Topics: Adult; Alendronate; Alveolar Bone Loss; Bone Density Conservation Agents; Bone Regeneration; Chi-Squ | 2012 |
Effect of alendronate on bone mineral density and biochemical markers of bone turnover in type 2 diabetic women: the fracture intervention trial.
Topics: Aged; Aged, 80 and over; Alendronate; Biomarkers; Body Mass Index; Bone Density; Diabetes Mellitus, | 2004 |
Clinical significance of alendronate in postmenopausal type 2 diabetes mellitus.
Topics: Aged; Alendronate; Bone Density; Collagen; Collagen Type I; Diabetes Mellitus, Type 2; Female; Human | 2004 |
Clinical and radiological improvement of periodontal disease in patients with type 2 diabetes mellitus treated with alendronate: a randomized, placebo-controlled trial.
Topics: Alendronate; Alveolar Bone Loss; Alveolar Process; Biomarkers; Bone Resorption; Case-Control Studies | 2001 |
13 other studies available for alendronate and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Alendronate Use and Risk of Type 2 Diabetes: A Nationwide Danish Nested Case-Control Study.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Case-Control Studies; Denmar | 2021 |
The Efficacy of Alendronate Versus Denosumab on Major Osteoporotic Fracture Risk in Elderly Patients With Diabetes Mellitus: A Danish Retrospective Cohort Study.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Cohort Studies; Denmark; Denosumab; Diabetes Me | 2021 |
General Commentary: Alendronate Use and Risk of Type 2 Diabetes: A Nationwide Nested Case-Control Study.
Topics: Alendronate; Bone Density Conservation Agents; Case-Control Studies; Denmark; Diabetes Mellitus, Typ | 2022 |
Alendronate inhibits triglyceride accumulation and oxidative stress in adipocytes and the inflammatory response of macrophages which are associated with adipose tissue dysfunction.
Topics: 3T3-L1 Cells; Adipocytes; Adipogenesis; Adipose Tissue; Alendronate; Animals; Cell Differentiation; | 2021 |
The use of alendronate is associated with a decreased incidence of type 2 diabetes mellitus--a population-based cohort study in Taiwan.
Topics: Alendronate; Body Mass Index; Bone Remodeling; Diabetes Mellitus, Type 2; Female; Humans; Incidence; | 2015 |
Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Angiogenesis Inhibitors; Anti-Bac | 2009 |
[Osteonecrosis of the jaw secondary to oral alendronate: Report of three cases].
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diabetes Mellitus, Type 2; F | 2009 |
Low 24-hour adiponectin and high nocturnal leptin concentrations in a case-control study of community-dwelling premenopausal women with major depressive disorder: the Premenopausal, Osteopenia/Osteoporosis, Women, Alendronate, Depression (POWER) study.
Topics: Adiponectin; Adrenocorticotropic Hormone; Adult; Alendronate; Body Mass Index; Case-Control Studies; | 2010 |
RETRACTED: Three-year experience with alendronate treatment in postmenopausal osteoporotic Japanese women with or without type 2 diabetes.
Topics: Aged; Aged, 80 and over; Alendronate; Asian People; Bone Density Conservation Agents; Case-Control S | 2011 |
Risk of newly diagnosed type 2 diabetes is reduced in users of alendronate.
Topics: Age of Onset; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Case-Control S | 2011 |
Dysmetabolic syndrome in a man with a novel mutation of the aromatase gene: effects of testosterone, alendronate, and estradiol treatment.
Topics: Acanthosis Nigricans; Adult; Alendronate; Aromatase; Arteriosclerosis; Bone and Bones; Cryptorchidis | 2004 |
Chronic kidney disease--a disease domain complex.
Topics: Aged; Alendronate; Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Asp | 2008 |
Considering competing risks . . . Not all black and white.
Topics: Alendronate; Atrial Fibrillation; Bone Density Conservation Agents; Decision Making; Diabetes Mellit | 2008 |